Stock Analiz

vTv Therapeutics Inc. VTVT

Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026

$19.69Market cap $79M
Open the interactive analysis →

vTv Therapeutics Inc. (VTVT) is a healthcare company listed in the US with a market value of about $79M. In the twelve months to September 30, 2026 it had revenue of $37M and net income of -$8M, a net margin of -20.8%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -103%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.

About vTv Therapeutics

vTv Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $2M in 2014 to $1M in 2024, a decline of about 4.1% a year. It was profitable in 0 of the last 10 years in our data.

Score: 1.0 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.1
P/B1.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−95%

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1029.8%
ROIC (5-yr avg.)-102.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$37M$0$1M$0$2M$4M$6M$3M$12M$291000$634000
Net income-$8M-$27M-$18M-$20M-$19M-$13M-$8M-$13M-$8M-$16M-$16M
Free cash flow——-$25M-$19M-$16M-$19M-$18M-$23M-$27M-$45M-$48M
EPS (diluted)$-1.91$-6.72—————————
Net margin-20.8%—-1815.3%—-949.6%-324.3%-132.5%-471.9%-63.6%-5547.8%-2579.2%
ROIC—-50.9%-154.4%————————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is vTv Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does vTv Therapeutics pay a dividend?

Not currently.

Is vTv Therapeutics a good stock to buy?

We do not give buy or sell advice. vTv Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.